Download PDF
Pharmacopsychiatry 2003; 36(1): 27-31
DOI: 10.1055/s-2003-38092
Original Paper
© Georg Thieme Verlag Stuttgart · New York

The High-affinity Non-peptide CRH1 Receptor Antagonist R121919 Attenuates Stress-induced Alterations in Plasma Oxytocin, Prolactin, and Testosterone Secretion in Rats

M. E. Keck1 , T. Welt1 , M. B. Müller1 , R. Landgraf1 , F. Holsboer1
  • 1Max Planck Institute of Psychiatry, Munich, Germany
Further Information

Publication History

Received: 20.2.2002 Revised: 11.4.2002

Accepted: 6.6.2002

Publication Date:
21 March 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Evidence from basic and clinical research suggests that hyperactivity of central corticotropin-releasing hormone (CRH) circuits contributes to causality and course of affective disorders. Therefore, CRH receptor antagonists have attracted attention as potential therapeutics. We could previously show that the novel high-affinity non-peptide CRH1 receptor antagonist R121919 significantly inhibits stress-induced corticotropin release and displays anxiolytic effects in rats selectively bred for high anxiety-related behavior. These animals are characterized by their innate hyper-reactivity of the hypothalamic-pituitary-adrenocortical system linked to an increased emotionality and therefore are suitable for the evaluation of CRH1 receptor antagonists. Here we show that in addition to its effects on anxiety-related behavior and corticotropin secretion, R121919 attenuates the stress-induced release of corticosterone, prolactin, and oxytocin. Moreover, the decrease in plasma testosterone following exposure to stress is abolished by R121919. Our data indicate that antagonism of CRH1 receptors may prevent stress-associated endocrine alterations.

Key words

Antidepressant - stress - depression - corticotropin-releasing hormone - corticotropin-releasing factor - corticotropin-releasing hormone receptor antagonist - testosterone - prolactin - oxytocin

References

  • 1 Akema T, Chiba A, Oshida M, Kimura F, Toyoda J. Permissive role of corticotropin-releasing factor in the acute stress-induced prolactin release in female rats.  Neurosci Let. 1995;  198 146-148
    CrossrefPubMedGoogle Scholar
  • 2 Bruhn T O, Sutton S W, Plotsky P M, Vale W W. Central administration of corticotropin-releasing factor modulates oxytocin secretion in the rat.  Endocrinology. 1986;  119 1558-1563
    PubMedGoogle Scholar
  • 3 Chatterton R T, Vogelsong K M, Lu Y C, Hudgens G A. Hormonal responses to psychological stress in men preparing for skydiving.  J Clin Endocrinol Metab. 1997;  82 2503-2509
    CrossrefPubMedGoogle Scholar
  • 4 Gerra G, Zaimovic A, Zambelli U, Timpano M, Reali N, Bernasconi S, Brambilla F. Neuroendocrine response to psychological stress in adolescents with anxiety disorder.  Neuropsychobiology. 2000;  42 82-92
    PubMedGoogle Scholar
  • 5 Heinrich N, Meyer M R, Furkert J, Sasse A, Beyermann M, Bönigk W, Berger H. Corticotropin-releasing factor (CRF) agonists stimulate testosterone production in mouse leydig cells through CRF receptor-1.  Endocrinology. 1998;  139 651-658
    CrossrefPubMedGoogle Scholar
  • 6 Heinrichs S C, Lapsansky J, Lovenberg T W, De Souza E B, Chalmers D T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior.  Reg Peptides. 1997;  71 15-21
    CrossrefPubMedGoogle Scholar
  • 7 Henniger M SH, Ohl F, Hölter S M, Weissenbacher P, Toschi N, Lörscher P, Wigger A, Spanagel R, Landgraf R. Unconditioned anxiety and social behaviour in two rat lines selectively bred for high and low anxiety-related behaviour.  Behav Brain Res. 2000;  111 53-163
    PubMedGoogle Scholar
  • 8 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.  J Psychiatr Res. 1999;  33 181-214
    CrossrefPubMedGoogle Scholar
  • 9 Imaki T, Katsumata H, Miyata M, Naruse M, Imaki J, Minami S. Expression of corticotropin releasing factor (CRF), urocortin and CRF type 1 receptors in hypothalamic-hypophyseal systems under osmotic stimulation.  J Neuroendocrinol. 2001;  13 328-338
    CrossrefPubMedGoogle Scholar
  • 10 Keck M E, Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders.  Peptides. 2001;  22 835-844
    CrossrefPubMedGoogle Scholar
  • 11 Keck M E, Hatzinger M, Wotjak C T, Holsboer F, Landgraf R, Neumann I D. Ageing alters intrahypothalamic release patterns of vasopressin and oxytocin in rats.  Eur J Neurosci. 2000;  12 1487-1494
    CrossrefPubMedGoogle Scholar
  • 12 Keck M E, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R. The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats.  Eur J Neurosci. 2001;  13 373-380
    CrossrefPubMedGoogle Scholar
  • 13 Keck M E, Wigger A, Welt T, Müller M B, Gesing A, Reul J MHM, Holsboer F, Landgraf R, Neumann I D. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders.  Neuropsychopharmacology. 2002;  26 94-105
    CrossrefPubMedGoogle Scholar
  • 14 Landgraf R. Neuropeptides and anxiety-related behavior.  Endocrine J. 2001;  48 517-533
    PubMedGoogle Scholar
  • 15 Lang R E, Heil J WE, Ganten D, Hermann K, Unger T, Rascher W. Oxytocin unlike vasopressin is a stress hormone in the rat.  Neuroendocrinology. 1983;  37 314-316
    PubMedGoogle Scholar
  • 16 Liebsch G, Landgraf R, Engelmann M, Lörscher P, Holsboer F. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain.  J Psychiatr Res. 1999;  33 153-63
    PubMedGoogle Scholar
  • 17 Liebsch G, Landgraf R, Gerstberger R, Probst J C, Wotjak C T, Engelmann M, Holsboer F, Montkowski A. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats.  Reg Peptides. 1995;  59 229-39
    CrossrefPubMedGoogle Scholar
  • 18 Liebsch G, Montkowski A, Holsboer F, Landgraf R. Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour.  Behav Brain Res. 1998;  94 301-310
    CrossrefPubMedGoogle Scholar
  • 19 Liebsch G, Montkowski A, Holsboer F, Landgraf R. Behavioral, physiological, and neuroendocrine stress responses and differential sensitivity to diazepam in two Wistar rat lines selectively bred for high and low anxiety-related behavior.  Neuropsychopharmacology. 1998;  19 81-396
    PubMedGoogle Scholar
  • 20 Lovenberg T W, Liaw C W, Grigoriadis D E, Clevenger W, Chalmers D T, De Souza E B, Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype.  Proc Acad Natl Sci USA. 1995;  92 36-40
    PubMedGoogle Scholar
  • 21 Maric D, Kostic T, Kovacevic R. Effects of acute and chronic immobilization stress on rat Leydig cell steroidogenesis.  J Steroid Biochem Mol Biol. 1996;  58 352-355
    PubMedGoogle Scholar
  • 22 Meyerhoff J L, Mougey E H, Kant G J. Paraventricular lesions abolish the stress-induced rise in pituitary cyclic adenosine monophosphate and attenuate the increases in plasma levels of proopiomelanocortin-derived peptides and prolactin.  Neuroendocrinology. 1987;  46 222-230
    PubMedGoogle Scholar
  • 23 Morel G, Enjalbert A, Proulx L, Pelletier G, Barden N, Grossard F, Dubois P M. Effect of corticotropin-releasing factor on the release and synthesis of prolactin.  Neuroendocrinology. 1989;  49 669-675
    PubMedGoogle Scholar
  • 24 Morgan C A, Wang S, Mason J, Southwick S M, Fox P, Hazlett G, Charney D S, Greefield G. Hormone profiles in humans experiencing military survival training.  Biol Psychiatry. 2000;  47 891-901
    CrossrefPubMedGoogle Scholar
  • 25 Müller M B, Keck M E. Genetically engineered mice for studies of stress-related clinical conditions.  J Psychiatr Res. 2002;  36 53-76
    CrossrefPubMedGoogle Scholar
  • 26 Müller M B, Preil J, Renner U, Zimmermann S, Kresse A E, Stalla G K, Keck M E, Holsboer F, Wurst W. Expression of CRHR1 and CRHR2 in mouse pituitary and adrenal gland: implications for HPA system regulation.  Endocrinology. 2001;  142 4150-4153
    CrossrefPubMedGoogle Scholar
  • 27 Neumann I D, Wigger A, Torner L, Holsboer F, Landgraf R. Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus.  J Neuroendocrinol. 2000;  12 235-243
    CrossrefPubMedGoogle Scholar
  • 28 Ohl F, Toschi N, Wigger A, Henniger M SH, Landgraf R. Dimensions of emotionality in a rat model of innate anxiety.  Behav Neurosci. 2001;  115 429-436
    CrossrefPubMedGoogle Scholar
  • 29 Pellow S, Chopin P, File S E, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.  J Neurosci Methods. 1985;  14 149-167
    CrossrefPubMedGoogle Scholar
  • 30 Perrin M H, Donaldson C; Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P, Vale W W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart.  Proc Natl Acad Sci USA. 1995;  92 969-29 739
    PubMedGoogle Scholar
  • 31 Raff H. Interactions between neurohypophyseal hormones and the ACTH-adrenocortical axis.  Ann N Y Acad Sci. 1993;  689 411-425
    PubMedGoogle Scholar
  • 32 Rho J h, Swanson L W. Neuroendocrine CRF motoneurons - intrahypothalamic axon terminals shown with a new retrograde-lucifer-immuno method.  Brain Res. 1987;  436 143-147
    CrossrefPubMedGoogle Scholar
  • 33 Sanchez M M, Young L J, Plotsky P M, Insel T R. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primates.  J Comp Neurol. 1999;  408 365-377
    PubMedGoogle Scholar
  • 34 Sattler H D, Richter P, Fritzsche M, von Turner A, Barnett W. Neurophysiologic testing during antidepressant treatment - an exploratory study.  Pharmacopsychiatry. 2000;  33 229-233
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Torner L, Toschi N, Pohlinger A, Landgraf R, Neumann I D. Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling.  J Neurosci. 2001;  21 3207-3214
    PubMedGoogle Scholar
  • 36 Tsai-Morris C H, Buczko E, Geng Y, Gamboa-Pinto A, Dufau M L. The genomic structure of the rat corticotropin releasing factor receptor - a member of the class II G protein-coupled receptors.  J Biol Chem. 1996;  271 14 519-14 525
    PubMedGoogle Scholar
  • 37 Ulisse S, Fabbri A, Tinajero J C, Dufau M L. A novel mechanism of action of corticotropin releasing factor in rat leydig cells.  J Biol Chem. 1990;  265 1964-1971
    PubMedGoogle Scholar
  • 38 Van Pett K, Viau V, Bittencourt J C, Chan R KW, Li H Y, Arias C, Prins G S, Perrin M, Vale W, Sawchenko P E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.  J Comp Neurol. 2000;  428 191-212
    PubMedGoogle Scholar
  • 39 Zobel A, Nickel T, Künzel H E, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.  J Psychiatr Res. 2000;  34 71-181
    PubMedGoogle Scholar

Dr. Martin E. Keck

Max Planck Institute of Psychiatry

Kraepelinstr. 2-10

D-80804 Munich

Germany

Phone: +49-89-30622-314

Fax: +49-89-30622-569

Email: keck@mpipsykl.mpg.de

      >